» Articles » PMID: 24155968

Kinetics of IL-6 Production Defines T Effector Cell Responsiveness to Regulatory T Cells in Multiple Sclerosis

Overview
Journal PLoS One
Date 2013 Oct 25
PMID 24155968
Citations 32
Authors
Affiliations
Soon will be listed here.
Abstract

In multiple sclerosis (MS) autoaggressive T effector cells (Teff) are not efficiently controlled by regulatory T cells (Treg) but the underlying mechanisms are incompletely understood. Proinflammatory cytokines are key factors facilitating Teff activity in chronic inflammation. Here we investigated the influence of IL-6 on Treg sensitivity of Teff from therapy-naïve MS patients with or without active disease. Compared to healthy volunteers and independent of disease course CD4(+) and especially CD8(+) MS-Teff were insensitive against functional active Treg from healthy controls. This unresponsiveness was caused by accelerated production of IL-6, elevated IL-6 receptor expression and phosphorylation of protein kinase B (PKB)/c-Akt in MS-Teff. In a positive feedback loop, IL-6 itself induced its accelerated synthesis and enhanced phosphorylation of PKB/c-Akt that finally mediated Treg resistance. Furthermore, accelerated IL-6 release especially by CD8(+) Teff prevented control of surrounding Teff, described here as "bystander resistance". Blockade of IL-6 receptor signaling or direct inhibition of PKB/c-Akt phosphorylation restored Treg responsiveness of Teff and prevented bystander resistance. In Teff of healthy controls (HC) exogenous IL-6 also changed the kinetics of IL-6 production and induced Treg unresponsiveness. This modulation was only transient in Teff from healthy volunteers, whereas accelerated IL-6 production in MS-Teff maintained also in absence of IL-6. Hence, we showed that the kinetics of IL-6 production instead of elevated IL-6 levels defines the Teff responsiveness in early Treg-T cell communication in MS independent of their disease course and propose IL-6 and associated PKB/c-Akt activation as effective therapeutic targets for modulation of Teff activity in MS.

Citing Articles

assessment of CAR macrophages activity against SARS-CoV-2 infection.

Amoddeo A Heliyon. 2024; 10(21):e39689.

PMID: 39524874 PMC: 11550025. DOI: 10.1016/j.heliyon.2024.e39689.


Tregs in transplantation tolerance: role and therapeutic potential.

Cassano A, Chong A, Alegre M Front Transplant. 2024; 2:1217065.

PMID: 38993904 PMC: 11235334. DOI: 10.3389/frtra.2023.1217065.


Effects of interleukin-6 signal inhibition on Treg subpopulations and association of Tregs with clinical outcomes in rheumatoid arthritis.

Yoshida H, Magi M, Tamai H, Kikuchi J, Yoshimoto K, Otomo K Rheumatology (Oxford). 2024; 63(9):2515-2524.

PMID: 38530780 PMC: 11371379. DOI: 10.1093/rheumatology/keae196.


Bystander activation of microglia by -infected astrocytes induces neuronal death via IL-6 trans-signaling.

Rodriguez J, De Santis Arevalo J, Dennis V, Rodriguez A, Giambartolomei G Front Immunol. 2024; 14:1343503.

PMID: 38322014 PMC: 10844513. DOI: 10.3389/fimmu.2023.1343503.


Cancer and Autoimmune Diseases as Two Sides of Chronic Inflammation and the Method of Therapy.

Rogovskii V Curr Cancer Drug Targets. 2024; 24(11):1089-1103.

PMID: 38288812 DOI: 10.2174/0115680096282480240105071638.


References
1.
Pierau M, Engelmann S, Reinhold D, Lapp T, Schraven B, Bommhardt U . Protein kinase B/Akt signals impair Th17 differentiation and support natural regulatory T cell function and induced regulatory T cell formation. J Immunol. 2009; 183(10):6124-34. DOI: 10.4049/jimmunol.0900246. View

2.
Cobbold S, Waldmann H . Infectious tolerance. Curr Opin Immunol. 1998; 10(5):518-24. DOI: 10.1016/s0952-7915(98)80217-3. View

3.
Hirano T . Interleukin 6 and its receptor: ten years later. Int Rev Immunol. 1998; 16(3-4):249-84. DOI: 10.3109/08830189809042997. View

4.
Vladic A, Horvat G, Vukadin S, Sucic Z, Simaga S . Cerebrospinal fluid and serum protein levels of tumour necrosis factor-alpha (TNF-alpha) interleukin-6 (IL-6) and soluble interleukin-6 receptor (sIL-6R gp80) in multiple sclerosis patients. Cytokine. 2002; 20(2):86-9. DOI: 10.1006/cyto.2002.1984. View

5.
Okuda Y, Sakoda S, Bernard C, Fujimura H, Saeki Y, Kishimoto T . IL-6-deficient mice are resistant to the induction of experimental autoimmune encephalomyelitis provoked by myelin oligodendrocyte glycoprotein. Int Immunol. 1998; 10(5):703-8. DOI: 10.1093/intimm/10.5.703. View